Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18

AbbVie reports results of 7.5-year pooled analysis of Imbruvica

AbbVie announced results of a 7.5-year pooled analysis showing earlier treatment with Imbruvica monotherapy compared to later lines of therapy extended progression-free survival and increased the likelihood of a complete response in patients with relapsed/refractory mantle cell lymphoma - "demonstrating that some patients achieved a disappearance of any signs of disease." The updated pooled analysis includes three clinical trials: Phase 2 SPARK, Phase 3 RAY and Phase 2 PCYC-1104. Patients achieving a CR with Imbruvica "had a strong response, with a median duration of therapy longer than 5.5 years" the company said.

  • 07

    Dec

ABBV AbbVie
$86.97

0.3 (0.35%)

12/03/19
PIPR
12/03/19
NO CHANGE
Target $92
PIPR
Overweight
Piper survey shows Rinvoq tracking meaningfully ahead of expectations
Piper Jaffray analyst Christopher Raymond raised his price target for AbbVie to $92 from $90 and keeps an Overweight rating on the shares. A new survey of 100 rheumatologists fielded by Piper's partner Spherix Global Insights indicates that Rinvoq uptake appears to be tracking meaningfully ahead of expectations, Raymond tells investors in a research note. While doctors see Rinvoq as meaningfully differentiated versus other JAKs, the famous "AbbVie halo" also appears to be at work here as rheumatologists explicitly cite the company's stewardship of this drug as a key reason for prescribing, adds the analyst.
11/22/19
ADAM
11/22/19
NO CHANGE
Target $26
ADAM
Buy
Harpoon Therapeutics price target raised to $26 from $22 at Canaccord
Canaccord Genuity analyst Arlinda Lee raised her price target for Harpoon Therapeutics (HARP) to $26 from $22 after the company and AbbVie (ABBV) expanded their existing collaboration and entered into a new agreement. The analyst views the agreement as further external validation of Harpoon's TriTAC platform, and she notes the company's $100M in near-term cash extends its runway well into the second half of 2022. Lee reiterates a Buy rating on Harpoon Therapeutics.
11/21/19
ROTH
11/21/19
NO CHANGE
ROTH
Buy
Roth says expanded pact a strong sign of AbbVie confidence in Harpoon platform
Roth Capital analyst Zegbeh Jallah said she believes Harpoon Therapeutics' (HARP) expanded agreement with AbbVie (ABBV) is both a strong indication of AbbVie's confidence in the platform as well as "a superb strategic move" for Harpoon. The new deal expands the existing October 2017 discovery and collaboration agreement while also establishing a new licensing and option agreement with Harpoon for HPN217, all while providing "an excellent source of additional cash" for Harpoon, Jallah tells investors. She has a Buy rating on Harpoon shares.
11/21/19
HCWC
11/21/19
NO CHANGE
HCWC
Harpoon two-part deal with AbbVie 'early, but impressive,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis called Harpoon Therapeutics' (HARP) two-part deal with AbbVie (ABBV) "early, but impressive," noting that the first part provides AbbVie with an option to license worldwide rights to HPN217 and the second expands their existing collaboration to include up to six additional targets. Pantginis does not have a rating on Harpoon shares, though he maintains a Buy rating on Arix Bioscience, which counts Harpoon among its portfolio companies. On Arix, he reiterates his Buy rating and 314 pence price target, stating that he continues to see a significant disconnect between the share price and the company's net asset value for its 14 portfolio companies.

TODAY'S FREE FLY STORIES

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOLS

Evolus

$11.43

0.25 (2.24%)

10:19
01/17/20
01/17
10:19
01/17/20
10:19
Recommendations
Evolus analyst commentary  »

Evolus shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEL

Velocity Financial

$0.00

(0.00%)

10:18
01/17/20
01/17
10:18
01/17/20
10:18
Syndicate
Breaking Syndicate news story on Velocity Financial »

Velocity Financial opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
01/17/20
01/17
10:17
01/17/20
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
01/17/20
01/17
10:16
01/17/20
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
U.S. JOLTS reported job openings dropped -561k to 6,800k in November »

U.S. JOLTS reported job…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

, GWB

Great Western

$34.30

-0.06 (-0.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

GWB

Great Western

$34.30

-0.06 (-0.17%)

TTEC

TTEC Holdings

$42.81

0.4 (0.94%)

BGNE

BeiGene

$169.94

2.055 (1.22%)

AMED

Amedisys

$181.47

0.28 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 28

    Jan

  • 04

    Feb

  • 27

    Feb

MS

Morgan Stanley

$56.87

0.42 (0.74%)

, TWTR

Twitter

$34.39

0.2 (0.58%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MS

Morgan Stanley

$56.87

0.42 (0.74%)

TWTR

Twitter

$34.39

0.2 (0.58%)

EBAY

eBay

$35.70

-0.21 (-0.58%)

CAKE

Cheesecake Factory

$39.21

-1.3 (-3.21%)

IBM

IBM

$137.21

-0.79 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 28

    Jan

  • 06

    Feb

  • 12

    Feb

WDC

Western Digital

$68.29

-0.33 (-0.48%)

, QCOM

Qualcomm

$93.76

1.99 (2.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

WDC

Western Digital

$68.29

-0.33 (-0.48%)

QCOM

Qualcomm

$93.76

1.99 (2.17%)

PINS

Pinterest

$23.36

0.4 (1.74%)

SNAP

Snap

$19.04

0.79 (4.33%)

YUM

Yum! Brands

$104.59

2.43 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

VEL

Velocity Financial

$0.00

(0.00%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Syndicate
Velocity Financial indicated to open at $13.70, IPO priced at $13.00 »

Velocity Financial (VEL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SNV

Synovus

$39.86

0.24 (0.61%)

10:12
01/17/20
01/17
10:12
01/17/20
10:12
Conference/Events
Synovus management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Feb

  • 26

    Feb

PWFL

PowerFleet

$8.20

-0.04 (-0.49%)

10:10
01/17/20
01/17
10:10
01/17/20
10:10
Conference/Events
PowerFleet management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.